Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Current Deferred Revenue for 3 consecutive years, with $402000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 94.53% year-over-year to $402000.0; the TTM figure through Dec 2025 stood at $402000.0 (down 94.53% YoY), while the FY2025 annual figure was $402000.0, down 94.23% from the prior year.
• Current Deferred Revenue retreated to $402000.0 in Q4 2025 per TLX's latest filing, from $7.4 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $7.4 million in Q4 2024 and bottomed at $402000.0 in Q4 2025.
• Historically, Current Deferred Revenue has averaged $5.0 million across 3 years, with a median of $7.2 million in 2023.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue gained 2.77% — and 2025, when it plunged 94.53%.
• Telix Pharmaceuticals' Current Deferred Revenue stood at $7.2 million in 2023, then climbed by 2.77% to $7.4 million in 2024, then slumped by 94.53% to $402000.0 in 2025.
• Business Quant data shows TLX's Current Deferred Revenue at $402000.0 in Q4 2025, $7.4 million in Q4 2024, and $7.2 million in Q4 2023.